Research Progress of Epigenetic Markers in Tumor Liquid Biopsy

LIU Hao¹, ZHOU Yun^2,3, LU Yuanyuan¹*

（¹State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, 710032, China; ²Department of Gastroenterology, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, China; ³College of Life Sciences, Northwest University, Xi’an 710069, China)

Abstract:

Compared with traditional tissue biopsy, liquid biopsy has many advantages, such as non-invasive, real-time dynamic monitoring, overcoming tumor heterogeneity, and so on. It is regarded as a promising tool for early screening and diagnosis of cancer. Tumor development and progression are accompanied by abnormal epigenetic changes, such as DNA methylation, histone modification, and non-coding RNA regulation. The detection of these epigenetic markers by liquid biopsy has been applied in early diagnosis and screening of tumors, recurrence monitoring, identification of tumor subtypes, and prediction of treatment response and outcomes, And it has shown great application prospects. This review summarizes the progress of epigenetic marker detection in tumor liquid biopsy

CSTR: 32200.14.cjcb.2023.12.0009